Results 321 to 330 of about 192,462 (340)
Some of the next articles are maybe not open access.
Role for Platelet-Activating Factor in Asthma
Lipids, 1991AbstractRecent studies of the effects of platelet‐activating factor (PAF) on huan and animal airways would support a putative role for this lipid mediator in asthma. PAF can induce many aspects of the clinical and pathological features seen in asthmatic airways such as airway oedema, eosinophil accumulation in the airway wall, and bronchial ...
Kian Fan Chung, Peter J. Barnes
openaire +2 more sources
Platelet-activating factor acetylhydrolase
Prostaglandins & Other Lipid Mediators, 2002Platelet-activating factor (PAF) is one of the most potent lipid mediators and is involved in a variety of physiological events. The acetyl group at the sn-2 position of its glycerol backbone is required for its biological activity, and deacetylation of PAF induces loss of activity. The deacetylation reaction is catalyzed by PAF-acetylhydrolase (PAF-AH)
openaire +3 more sources
Embryo-derived platelet activating factor
Reproduction, Fertility and Development, 1988Platelet-activating factor (PAF) is secreted by the preimplantation embryo of a number of species. The role of this secretion is yet to be fully elucidated. Evidence to date indicates that it has an important function as an autocrine stimulant of embryonic metabolism, growth and viability. Production of PAF by embryos appears to be severely compromised
C. O’Neill, N. Spinks
openaire +3 more sources
A superfusion bioassay for platelet-activating factor
Canadian Journal of Physiology and Pharmacology, 1989A superfusion bioassay for platelet-activating factor is described using various types of tissues. By washing the tissue with 0.1–0.5% bovine serum albumin for 2–3 min after each addition of platelet-activating factor, desensitization did not develop in most tissues studied.
CIRINO, GIUSEPPE, J. L. Wallace
openaire +4 more sources
2016
Platelet-activating factor (PAF) is a phospholipid produced by a variety of cells including platelets, endothelial cells, neutrophils, monocytes and macrophages. It has a wide range of potent biological activities including wound healing, physiological inflammation, apoptosis, angiogenesis, reproduction and long-term potentiation.
openaire +2 more sources
Platelet-activating factor (PAF) is a phospholipid produced by a variety of cells including platelets, endothelial cells, neutrophils, monocytes and macrophages. It has a wide range of potent biological activities including wound healing, physiological inflammation, apoptosis, angiogenesis, reproduction and long-term potentiation.
openaire +2 more sources
Cardiovascular Effects of Platelet-Activating Factor
Lipids, 1991AbstractSudden release of platelet‐activating factor (PAF) into the circulation can cause hypotension, tachycardia, and circulatory collapse. To further examine this response, we performed detailed studies of cardiovascular function after PAF administration to young domestic pigs and newborn piglets.
Nancy J. Davenport +5 more
openaire +3 more sources
Pathobiology of Platelet-Activating Factors
Pathology and Immunopathology Research, 1986Throughout the evolution of knowledge about inflammation, a primary goal has been to understand this important biological response in sufficient depth to prevent the unwanted tissue injury that may spontaneously occur or that may coevolve to produce disease.
openaire +3 more sources
Immunopharmacology, 1988
Platelet activating factor (PAF) was found to suppress primary and secondary mixed lymphocyte reactions and BN52021, a naturally occurring PAF antagonist, blocked PAF-mediated suppression and enhanced the mixed lymphocyte reactions. The effect of delayed addition of PAF or BN52021 24 h or later after the initiation of cultures reduced the suppressive ...
Pierre Braquet +3 more
openaire +3 more sources
Platelet activating factor (PAF) was found to suppress primary and secondary mixed lymphocyte reactions and BN52021, a naturally occurring PAF antagonist, blocked PAF-mediated suppression and enhanced the mixed lymphocyte reactions. The effect of delayed addition of PAF or BN52021 24 h or later after the initiation of cultures reduced the suppressive ...
Pierre Braquet +3 more
openaire +3 more sources
Life Sciences, 1988
Renovascular hypertension is relieved by percutaneous transluminal renal angioplasty. In four patients with renovascular hypertension, platelet-activating factor (PAF) was found to be released into the ipsilateral renal venous blood after percutaneous transluminal renal angioplasty, but was not found in the contralateral renal venous blood following ...
Katsuhiko Sakaguchi +8 more
openaire +3 more sources
Renovascular hypertension is relieved by percutaneous transluminal renal angioplasty. In four patients with renovascular hypertension, platelet-activating factor (PAF) was found to be released into the ipsilateral renal venous blood after percutaneous transluminal renal angioplasty, but was not found in the contralateral renal venous blood following ...
Katsuhiko Sakaguchi +8 more
openaire +3 more sources
Paf-acether (Platelet-activating Factor)
1986Platelet-activating factor was first described as originating from IgE-sensitized rabbit basophils challenged with the specific allergen. When its structure, 1-O- alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine was unveiled in 1979, it was thus named “Paf-acether”, given the ether linkage at position 1 and the acetyl group at position 2 of glycerol. Paf-
openaire +5 more sources